

### **EXHIBIT HALL PRODUCT THEATERS**

Product Theaters feature exhibitor presentations on new research findings and products to small groups of annual meeting attendees (no more than 150) within the exhibit hall. The Product Theater sessions will be solely promotional in nature; therefore, continuing medical education credits will not be offered. ASH will provide lunch during each theater. Please bring your Sunday and/or Monday exhibit hall lunch ticket to the applicable product theater.

Saturday, December 3, 2016 11:30 a.m. to 12:30 p.m.

Sponsored by: Pfizer Oncology

Treatment of Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia (CML) Resistant or Intolerant to Prior Therapy, Patient Journeys

**Speaker:** Fiona An, MD, Senior Director of Medical Affairs, Pfizer Oncology

**Product Theater #1** (back of the 3700 aisle)

Sponsored by: American Regent, Inc.

#### Combating Iron Deficiency Anemia: Emerging Trends in Treatment Options

**Speaker:** Linda M. Mundy, MD, PhD, FACP, Vice President and Chief Medical Officer, Luitpold Pharmaceuticals, Inc.

Product Theater #2 (back of the 2300 aisle)
\*This presentation is intended for U.S.-based attendees

Sponsored by: Amgen

#### Current landscape in minimal residual disease (MRD) testing in hematologic malignancies

**Speaker:** Jonathan Benjamin, MD, PhD, Clinical Research Medical Director, Amgen **Product Theater #3**(front of the 1600 aisle)

Sunday, December 4, 2016 11:30 a.m. to 12:30 p.m.

Sponsored by: Takeda Oncology

## NINLARO® (ixazomib): an oral treatment option

#### Speakers:

Antonio Palumbo, MD, Distinguished Research Fellow Oncology, Global Medical Affairs, Takeda Oncology

Stephen J. Noga, MD, PhD, Senior Medical Director, Global Affairs, Takeda Oncology

Product Theater #1 (back of the 3700 aisle)

Sponsored by: Pharmacyclics

#### Pharmacyclics and Janssen Hematology Program

**Speaker:** Jason Dubovsky, Ph.D., Scientist II, Pharmacyclics **Product Theater #2** (back of the 2300 aisle)

Sponsored by: Genentech

#### Treatment for relapsed/ refractory Follicular Lymphoma (FL)

**Speaker:** Sandra Horning, MD, Executive Vice President, Global Head of Product Development and Chief Medical Officer, Genentech USA, Inc. **Product Theater #3** (front of the 1600 aisle) Presented by: Janssen Biotech, Inc.

DARZALEX™

Monday, December 5, 2016

12:15 p.m. to 1:15 p.m.

# (daratumumab) - A Treatment Option for Patients With Multiple Myeloma Who Have Failed Multiple Therapies

**Speaker:** Manish Sharma MD, Associate Director, HEME Malignancy, Medical Group Oncology, Janssen Biotech, Inc. **Product Theater #1** 

(back of the 3700 aisle)
\*This presentation is intended for U.S.-based attendees

Sponsored by: Shire

## Julie M: A Diagnostic Journey

**Speaker:** Quinn Dinh, MD, Head US Genetic Disease Medical, Shire Medical Affairs

Product Theater #2

(back of the 2300 aisle) \*This presentation is intended for U.S.-based attendees

Sponsored by: AbbVie

#### Scientific Rationale for Targeting BCL-2 in Deletion 17p CLL Patients

**Speaker:** Rod Humerickhouse, MD, PhD, AbbVie Group Project Leader, Oncology Pharmaceutical Development

Product Theater #3 (front of the 1600 aisle) \*This presentation is intended for U.S.-based attendees